Abstract:Synthetic peptide‐based vaccine strategies are reviewed in the context of anticancer intervention, focusing on critical aspects such as peptide epitope selection, adjuvant integration, and nuanced classification of synthetic peptide cancer vaccines. The potential synergy of peptide‐based vaccines with common therapeutics in cancer is also considered. The present review focuses on synthetic peptide‐based vaccine strategies in the context of anticancer intervention, paying attention to critical aspects such as peptide epitope selection, adjuvant integration, and nuanced classification of synthetic peptide cancer vaccines. Within this discussion, we delve into the diverse array of synthetic peptide‐based anticancer vaccines, each derived from tumor‐associated antigens (TAAs), including melanoma antigen recognized by T cells 1 (Melan‐A or MART‐1), mucin 1 (MUC1), human epidermal growth factor receptor 2 (HER‐2), tumor protein 53 (p53), human telomerase reverse transcriptase (hTERT), survivin, folate receptor (FR), cancer‐testis antigen 1 (NY‐ESO‐1), and prostate‐specific antigen (PSA). We also describe the synthetic peptide‐based vaccines developed for cancers triggered by oncovirus, such as human papillomavirus (HPV), and hepatitis C virus (HCV). Additionally, the potential synergy of peptide‐based vaccines with common therapeutics in cancer was considered. The last part of our discussion deals with the realm of the peptide‐based vaccines delivery, highlighting its role in translating the most promising candidates into effective clinical strategies. Although this discussion does not cover all the ongoing peptide vaccine investigations, it aims at offering valuable insights into the chemical modifications and the structural complexities of anticancer peptide‐based vaccines.

Peptide‐based therapeutic cancer vaccine: Current trends in clinical application

Analysis of the development prospects of cancer therapeutic vaccines based on the current research status of peptide vaccines

Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective

Clinical Application of Peptide Vaccine for Cancer

Peptide-based vaccine for cancer therapies

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

Peptide-Based Treatment: A Promising Cancer Therapy

Development of tumour peptide vaccines: From universalization to personalization

The Role and Development of Peptide Vaccines in Cervical Cancer Treatment

Therapeutic cancer vaccines: advancements, challenges, and prospects

Recent Advances in Peptide-Based Therapeutic Strategies for Breast Cancer Treatment.

Peptide-Based Cancer Vaccine Strategies and Clinical Results

Personalized Neoantigen Vaccination with Synthetic Long Peptides: Recent Advances and Future Perspectives

The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

Advances in Cancer Vaccine Research

Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Peptide Therapeutics and Assemblies for Cancer Immunotherapy

Advances in Research on Antitumor Activities of HER2-based Peptide Vaccines

Advances in therapeutic cancer vaccines: harnessing immune adjuvants for enhanced efficacy and future perspectives

Therapeutic Vaccines for Cancer Immunotherapy